Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...

Wall Street’s main indexes slipped on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

US Stocks Market fall as weak US retail sales, housing, and industrial data add to fears of a slowdown, while Middle East ...

U.S. stocks are drifting lower, while oil prices are rising again. The S&P 500 fell 0.3% Tuesday. The Dow Jones Industrial ...